Reduced post-transplant cyclophosphamide doses in haploidentical hematopoietic cell transplantation for elderly patients with hematological malignancies [0.03%]
老年血液恶性肿瘤患者在半同卵造血细胞移植后降低环磷酰胺的剂量
Rémy Duléry,Claire Goudet,Daniele Mannina et al.
Rémy Duléry et al.
Although post-transplant cyclophosphamide (PT-Cy) is effective for graft-versus-host disease (GVHD) prophylaxis, it is associated with toxicities, which might be dose-dependent. We compared the outcomes with PT-Cy at 80 mg/kg to those with ...
Comparison of reduced intensity and nonmyeloablative conditioning for adults with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation in first or second remission [0.03%]
急性髓系白血病成人患者在首次或二次缓解时进行异体造血细胞移植时，降低强度与非清髓性预处理的比较研究
Roland B Walter,Brenda M Sandmaier,Megan Othus et al.
Roland B Walter et al.
Reduced intensity conditioning (RIC) and nonmyeloablative (NMA) conditioning regimens have expanded use of allogeneic hematopoietic cell transplantation (HCT) in AML to include older and medically less-fit patients, but relative efficacies ...
CD19 CAR-T therapy in solid organ transplant recipients: case report and systematic review [0.03%]
实体器官移植受者中CD19嵌合抗原受体T细胞治疗的病例报告及系统综述
Andrew J Portuguese,Jordan Gauthier,Scott S Tykodi et al.
Andrew J Portuguese et al.
Post-transplant lymphoproliferative disorder (PTLD) is a leading cause of cancer death in solid organ transplant recipients (SOTRs). Relapsed or refractory (R/R) PTLD portends a high risk of death and effective management is not well establ...
Impact of standard-dose dipeptidyl peptidase-4 inhibitors on the incidence of graft-versus-host disease after allogeneic hematopoietic cell transplantation [0.03%]
标准剂量二肽基肽酶-4抑制剂对异基因造血细胞移植后移植物抗宿主病发生率的影响
Shun-Ichi Kimura,Hiroaki Shimizu,Takuya Miyazaki et al.
Shun-Ichi Kimura et al.
Real-world use of defibrotide for veno-occlusive disease/sinusoidal obstruction syndrome: the DEFIFrance Registry Study [0.03%]
DEFIFrance 注册研究：defibrotide 用于静脉闭塞病/窦状隙阻塞综合征的实际应用
Mohamad Mohty,Didier Blaise,Régis Peffault de Latour et al.
Mohamad Mohty et al.
Veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS) is a potentially life-threatening complication of haematopoietic cell transplantation (HCT) conditioning. The DEFIFrance post-marketing registry study evaluated effectiveness ...
Allogeneic stem cell transplantation combined with conditioning regimen including donor-derived CAR-T cells for refractory/relapsed B-cell lymphoma [0.03%]
allo-HSCT联合供者CAR-T细胞预处理方案治疗复发难治B细胞淋巴瘤
Fan Yang,Hui Shi,Teng Xu et al.
Fan Yang et al.
Clinical outcome of patients with relapsed refractory multiple myeloma listed for BCMA directed commercial CAR-T therapy [0.03%]
接受BCMA导向的CAR-T治疗的复发难治性多发性骨髓瘤患者的临床结果研究
Samer Al Hadidi,Aniko Szabo,Jean Esselmann et al.
Samer Al Hadidi et al.
Autologous hematopoietic cell transplantation as a part of a sequential multi-phase therapeutic approach (R-COPADM/CYVE/ASCT) as first-line treatment of high-grade B-cell lymphoma: results of a retrospective study with long-term follow-up [0.03%]
自体造血细胞移植作为多阶段治疗方案（R-COPADM / CYVE / ASCT）的一部分用于B细胞淋巴瘤的一线治疗：长期随访的回顾性研究结果
Tamim Alsuliman,Nicolas Stocker,Elise Corre et al.
Tamim Alsuliman et al.
Patients with high-risk lymphoma have a poor prognosis when treated with standard chemoimmunotherapy. This retrospective study included 23 high-risk lymphoma patients with a median age at diagnosis of 59 (range, 35-68) years. They received ...
Pneumocystis jirovecii Infection in autologous hematopoietic stem cell transplant recipients [0.03%]
自体造血干细胞移植受者中的卡氏肺孢子虫感染
John Coda,Kadee Raser,Sarah M Anand et al.
John Coda et al.